These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38758900)

  • 81. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Zhang K; Sun X; Xie F; Jian W; Li C
    J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
    World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 85. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
    Zheng J; Shao G; Luo J
    Clin Transl Oncol; 2014 Nov; 16(11):1012-7. PubMed ID: 24894839
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A.
    Jin YJ; Lee JW; Choi YJ; Chung HJ; Kim YS; Lee KY; Ahn SI; Shin WY; Cho SG; Jeon YS
    J Gastrointest Surg; 2014 Mar; 18(3):555-61. PubMed ID: 24420729
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
    Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
    J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
    Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
    Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 96. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
    Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.
    Schindler P; Kaldewey D; Rennebaum F; Trebicka J; Pascher A; Wildgruber M; Köhler M; Masthoff M
    J Cancer Res Clin Oncol; 2024 May; 150(5):235. PubMed ID: 38710956
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
    Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
    BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
    Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma.
    Kong JY; Li SM; Fan HY; Zhang L; Zhao HJ; Li SM
    Medicine (Baltimore); 2018 Aug; 97(33):e11872. PubMed ID: 30113483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.